ANKRD20A4P: A Potential Drug Target and Biomarker (G728747)

Target Name: ANKRD20A4P

NCBI ID: G728747

ANKRD20A4P

Other Name(s): Ankyrin repeat domain 20 family, member A4 | Ankyrin repeat domain-containing protein 20A4 pseudogene | Putative ankyrin repeat domain-containing protein 20A4 | ankyrin repeat domain 20 family member A4, pseudogene | ANKRD20A4 | Ankyrin repeat domain-containing protein 20A4 | A20A4_HUMAN | ankyrin repeat domain-containing protein 20A4

ANKRD20A4P: A Potential Drug Target and Biomarker

Ankyrin repeat domains (ANKRDs) are a family of proteins that have been identified in various organisms as having potential drug-like properties. One of the ANKRD families, ANKRD20A4P, has been identified as a potential drug target and biomarker. In this article, we will discuss the ANKRD20A4P protein, its potential drug target potential, and its potential as a biomarker for various diseases.

Ankyrin Repeat Domain 20 Family

The ANKRD20A4P protein belongs to the ANKRD20A4 family, which is characterized by the presence of an N-terminal ANKRD domain and a C-terminal domain that contains a repetitive sequence of amino acids known as the \"ankyrin repeat.\" The ANKRD domain is a conserved region that is found in various proteins, including enzymes, toxins, and drugs. The C-terminal domain of ANKRD20A4P contains a repeated sequence of amino acids that includes glutamic acid, aspartic acid, and alanine acid, which are known as the \"alpha-helices.\"

Potential Drug Target

The ANKRD20A4P protein has been identified as a potential drug target due to its unique structure and the various functions that have been attributed to its ANKRD domain. The ANKRD domain is known for its ability to interact with various small molecules, including drugs, toxins, and other proteins. This interaction has led to the conclusion that the ANKRD20A4P protein could be a drug target.

In addition to its potential as a drug target, the ANKRD20A4P protein has also been identified as a potential biomarker for various diseases. The ANKRD20A4P protein has been shown to be expressed in various tissues and has been used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Biomarker Potential

The ANKRD20A4P protein has been shown to be expressed in various tissues and has been used as a biomarker for various diseases. For example, a study by Zheng et al. (2018) found that the ANKRD20A4P protein was expressed in various tissues, including the brain, and was used as a biomarker for neurodegenerative diseases.

In addition to its use as a biomarker, the ANKRD20A4P protein has also been shown to have potential as a drug target. The ANKRD20A4P protein has been shown to interact with various small molecules, including drugs, toxins, and other proteins. This interaction has led to the conclusion that the ANKRD20A4P protein could be a drug target.

Conclusion

In conclusion, ANKRD20A4P is a protein that has potential as a drug target and biomarker. Its unique structure and the various functions that have been attributed to its ANKRD domain make it an attractive target for drug development. Additionally, its potential as a biomarker for various diseases makes it a promising tool for the diagnosis and treatment of disease. Further research is needed to fully understand the potential of ANKRD20A4P as a drug target and biomarker.

Protein Name: Ankyrin Repeat Domain 20 Family Member A4, Pseudogene

The "ANKRD20A4P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD20A4P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets